Phase I Study With Sorafenib in Addition to Vinflunine in Metastatic Transitional Cell Carcinoma of the Urothelial Tract

NCT01844947 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

22

Enrollment

OTHER

Sponsor class

Conditions

Urothelial Carcinoma
Bladder Cancer
Renal Pelvis Cancer
Ureter Cancer
Urethra Cancer

Interventions

DRUG: Vinflunine
DRUG: Sorafenib

Sponsor

Dr Anders Ullén

Collaborators

[object Object]
[object Object]
[object Object]